Irvine, CA, USA, March 30th, 2026, FinanceWire
Helio Genomics announces new HelioLiver access through Quest, expanding the availability of its blood-based liver cancer test to providers across the United States.
Expanded Provider Access Begins in April
The new arrangement is expected to make HelioLiver available to healthcare providers with a Quest account beginning in April. Through Quest’s existing infrastructure, providers will be able to order the test within a system that many already use in routine care.
For Helio Genomics, the agreement marks a broader commercial step for HelioLiver, its blood-based test for early detection of hepatocellular carcinoma, the most common form of primary liver cancer. The move also places the test inside a much larger national provider network, widening the company’s reach beyond a narrower direct-access model.
A Blood-Based Test Aimed at Earlier Detection
Helio Genomics says HelioLiver is meant to fit into routine liver cancer surveillance through a simple blood draw. The test combines cell-free DNA methylation patterns, protein biomarkers, and patient demographics in a proprietary AI-driven algorithm.
The company presents that combination as an additional source of disease risk signal at an early stage, with particular relevance in settings where ultrasound results may still leave room for uncertainty. That positioning connects the test to ongoing monitoring. HelioLiver is aimed toward people at risk of hepatocellular carcinoma, including patients with cirrhosis or hepatitis B, where liver cancer surveillance may already be a part of clinical care.
Quest Arrangement and Service Integration
Under the agreement, Quest’s provider clients are expected to be able to access HelioLiver through their existing Quest account and electronic health record systems. Sample collection may also be supported through Quest’s approximately 7,700 patient services and in-office phlebotomists across the United States.
Helio Genomics said testing will continue to be performed at its laboratory in West Lafayette, Indiana. The arrangement expands access through ordering and collection infrastructure while keeping the analytical work within Helio’s own laboratory operations.
Liver Cancer Screening Challenges and Context
The agreement arrives amid growing concern around liver cancer detection. Helio Genomics notes that liver cancer often goes undetected until later stages because early symptoms may be absent. The company also points to screening barriers tied to inconvenience, access, and follow-through.
That context shapes how HelioLiver is being introduced. Its blood-based format is presented as a way to fit more easily into surveillance workflows for at-risk patients. The emphasis remains on practical access, early identification, and giving providers another testing option within an established care network.
Company Statements on the Agreement
Dr. Bharat Tewarie, CEO of Helio Genomics, said the agreement with Quest Diagnostics represents an important step in the company’s effort to widen access to early cancer detection tools and support physicians in identifying liver cancer at a more treatable stage.
Asia Chang, vice president and general manager of oncology at Quest Diagnostics, said the collaboration reflects Quest’s view that liquid biopsy may play a meaningful role in aiding earlier cancer detection. The goal is to help reach more patients and care teams through Quest’s national scale.
About Helio Genomics
Helio Genomics is a commercial-stage, AI-driven TechBio company focused on early cancer detection and minimal residual disease monitoring. Its blood-based platform uses machine learning and deep learning to identify cancer biomarkers for clinical use.